Susquehanna International Group, LLP Black Diamond Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $641 Billion
- Q4 2024
A detailed history of Susquehanna International Group, LLP transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 34,672 shares of BDTX stock, worth $79,052. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,672
Previous 70,500
50.82%
Holding current value
$79,052
Previous $306,000
75.82%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
47.6MCall Options Held
2.9KPut Options Held
69.4K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$23.9 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$19.4 Million0.36% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$12.8 Million0.71% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$10.1 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$7.34 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $82.9M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...